Review Article
Current Status of Poly(ADP-ribose) Polymerase Inhibitors as Novel Therapeutic Agents for Triple-Negative Breast Cancer
Table 1
Partial list of ongoing clinical trials for PARP inhibitors on TNBC.
| Drug/company | Trial ID | Trial | Phase |
| Olaparib (AZD2281)/AstraZeneca | NCT01116648 | Cediranib and olaparib | II | NCT00647062 | AZD2281 and carboplatin | I | NCT00516724 | In combination with carboplatin and/or paclitaxel | I | NCT00707707 | In combination with paclitaxel | I | NCT00679783 | In known BRCA/TNBC | II |
| Iniparib (BSI-201)/Sanofi-Aventis | NCT01173497 | Iniparib + irinotecan | II | NCT00813956 | Neoadjuvant with gemcitabine and carboplatin | II | NCT01045304 | Metastatic with gemcitabine and carboplatin | II | NCT01204125 | Neoadjuvant with paclitaxel | II | NCT01130259 | In combination with gemcitabine and carboplatin | III |
| Veliparib (ABT-888)/Abbott | NCT01009788 | With temozolomide | II | NCT01104259 | With cisplatin and vinorelbine ditartrate | I | NCT01306032 | With cyclophosphamide | II | NCT01042379 | I-SPY2 trial | II | NCT01251874 | With carboplatin | I |
|
|
Data obtained from http://www.clinicaltrials.gov, June 15, 2011.
|